Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab170483-100μg
|
100μg |
10
|
$109.90
|
|
|
Ab170483-1mg
|
1mg |
4
|
$507.90
|
|
|
Ab170483-5mg
|
5mg |
1
|
$1,377.90
|
|
|
Ab170483-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$2,187.90
|
|
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Monalizumab (anti-NKG2A) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to NKG2A, >95%, high purity, Human IgG4SP, Antibody of killer cell lectin like receptor C1 (CD159a) |
|---|---|
| Synonyms | CD159 antigen-like family member A | CD159a antigen | CD159a | C-lectin type II protein | killer cell lectin-like receptor subfamily C, member 1 | Klrc1 | MGC13374 | natural killer cell lectin | natural killer group protein 2 | NK cell receptor A | NKG2 | |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Host species | Human |
| Specificity | NKG2A |
| Application | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | INHIBITOR |
| Mechanism of action | Antibody of killer cell lectin like receptor C1 (CD159a) |
| Product Description |
Monalizumab is a first-in-class immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC). |
| Antibody Type | Primary antibody |
|---|---|
| Clonality | Recombinant |
| Isotype | Human IgG4SP |
| Light Chain Type | kappa |
| SDS-PAGE | 26.4 kDa (Light Chain) & 52.1 kDa (Heavy Chain), under reducing conditions; 175.2 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Source | CHO supernatant |
| Shape | Liquid |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| CAS | 1228763-95-8 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Monalizumab (anti-NKG2A) (Ab170483) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling NKG2A (red) with Monalizumab (anti-NKG2A) (Ab170483). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Monalizumab (anti-NKG2A) (Ab170483) - SEC
The purity of Monalizumab (anti-NKG2A) (Ab170483) is more than 95% verified by HPLC.
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | Mar 25, 2024 | Ab170483 | |
| Certificate of Analysis | Mar 25, 2024 | Ab170483 | |
| Certificate of Analysis | Mar 25, 2024 | Ab170483 |